2024 SABCS Highlights

CME

CCO Independent Conference Highlights of the 2024 San Antonio Breast Cancer Symposium

Physicians: Maximum of 1.50 AMA PRA Category 1 Credits

Released: March 04, 2025

Expiration: September 03, 2025

Activity

Progress
1 2
Course Completed

References

  1. Garber J. GS1-09: OlympiA: a phase 3, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients w/germline BRCA1 & BRCA2 pathogenic variants & high risk HER2-negative primary breast cancer. Presented at: 2024 San Antonio Breast Cancer Symposium; December 10-13, 2024. Abstract GS1-09.
  2. Tutt ANJ, Garber JE, Kaufman B, et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med. 2021;384:2394-2405.
  3. Geyer CE, Garber JE, Gelber RD, et al. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. Ann Oncol. 2022;33:1250-1268.
  4. Fasching PA, Stroyakovskiy D, Yardley D, et al. Adjuvant ribociclib (RIB) plus nonsteroidal aromatase inhibitor (NSAI) in patients with HR+/HER2- early breast cancer (EBC): 4-year outcomes from the NATALEE trial. Ann Oncol. 2024;35(suppl 2):S1207.
  5. Hamilton E, Decker T, Rugo HS, et al. Impact of ribociclib dose reduction on efficacy in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer in NATALEE. Presented at: 2024 San Antonio Breast Cancer Symposium; December 10-13, 2024. Abstract P1-11-16.
  6. Hurvitz SA, Jarzab M, Munoz Mateu M, et al. Distant disease-free survival across key subgroups from the phase 3 NATALEE trial of ribociclib plus a nonsteroidal aromatase inhibitor in patients with HR+/HER2- early breast cancer. Presented at: 2024 San Antonio Breast Cancer Symposium; December 10-13, 2024. Abstract P4-09-22.
  7. Oliveira M, Pascual T, Amillano K, et al. Neoadjuvant HER3-DXd alone or in combination with letrozole for high-risk HR+/HER2- early EBC: primary results of the randomized phase II SOLTI VALENTINE trial. Presented at: 2024 San Antonio Breast Cancer Symposium; December 10-13, 2024. Abstract LB1-06.
  8. Tolaney SM, Sammons S, Cortes J, et al. Risk of recurrence by nodal status and high-risk features in patients with HR+, HER2-, early breast cancer: an analysis of real-world data. Presented at: 2024 San Antonio Breast Cancer Symposium; December 10-13, 2024. Abstract P1-11-02.
  9. Ribociclib [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2023.
  10. Rastogi P, O’Shaughnessy J, Martin M, et al. Adjuvant abemaciclib plus endocrine therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative, high-risk early breast cancer: results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes. J Clin Oncol. 2024;42:987-993.
  11. Loibl S, Thill M, Rey J, et al Primary results of the randomised phase IV trial comparing first-line ET plus palbociclib vs standard mono-chemotherapy in women with high-risk HER2-/HR+ metastatic breast cancer and indication for chemotherapy – PARDMA study. Presented at: 2024 San Antonio Breast Cancer Symposium; December 10-13, 2024. Abstract LB1-03.
  12. Lu Y-S, Izwadi E, Mahidin BM, et al. Final results of RIGHT Choice: ribociclib plus endocrine therapy versus combination chemotherapy in premenopausal women with clinically aggressive hormone receptor-positive/human epidermal growth factor receptor-2 negative advanced breast cancer. J Clin Oncol. 2024;42:2812-2821.
  13. Lu Y-S, Shu C-L, Chen EL, et al. First-line ribociclib + endocrine therapy vs combination chemotherapy in clinically aggressive HR+/HER2- advanced breast cancer: a subgroup analysis of RIGHT Choice by intrinsic subtype and gene and signature expression. Presented at: 2024 San Antonio Breast Cancer Symposium; December 10-13, 2024. Abstract PS2-06.
  14. Jhaveri KL, Neven P, Casalnuovo ML, et al. Imlunestrant with or without abemaciclib in advanced breast cancer. N Engl J Med. 2024;[Epub ahead of print.]
  15. Jhaveri KL, Neven P, Casalnuovo ML, et al. Imlunestrant, an oral selective estrogen receptor degrader (SERD), as monotherapy & combined with abemaciclib, for patients with ER+, HER2- advanced breast cancer (ABC), pretreated with endocrine therapy (ET): results of the phase 3 EMBER-3 trial. Presented at: 2024 San Antonio Breast Cancer Symposium; December 10-13, 2024. Abstract GS1-01.
  16. Turner NC, Im SA, Saura C, et al. Inavolisib-based therapy in PIK3CA-mutated advanced breast cancer. N Engl J Med. 2024;391:1584-1596.
  17. Inavolisib [prescribing information]. South San Francisco, CA: Genentech, Inc; 2024.
  18. Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med. 2011;62:233-247.
  19. Glaviano A, Foo ASC, Lam HY, et al. PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer. Mol Cancer. 2023;22:138.
  20. Brett JO, Spring ML, Bardia A, et al. ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer. Breast Cancer Res. 2021;23:85.
  21. Bidard FC, Hardy-Bessard AC, Dalenc F, et al. Switch to fulvestrant and palbociclib vs no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase III trial. Lancet Oncol. 2022;23:1367.
  22. Elacestrant [prescribing information]. New York, NY: Stemline Therapeutics; 2023.
  23. Rugo HS, Tolaney SM, Chan N, et al. Elacestrant combinations in patients with estrogen receptor-positive (ER+), HER2-negative (HER2-) locally advanced or metastatic breast cancer (mBC): update from ELEVATE, a phase 1b/2, open-label, umbrella study. Presented at: 2024 San Antonio Breast Cancer Symposium; December 10-13, 2024. Abstract PS7-07.  
  24. Rugo HS, Tolaney SM, Chan N, et al. Elacestrant plus abemaciclib (abeam) combination in patients (pts) with estrogen receptor-positive (ER+), HER2-negative (HER2-) advanced or metastatic breast cancer (mBC). Presented at: 2024 San Antonio Breast Cancer Symposium; December 10-13, 2024. Abstract PS7-06. 
  25. Curigliano G, Hu X, Dent RA, et al. Trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): primary results from DESTINY-Breast06 (DB-06). Presented at: 60th Annual Meeting of the American Society of Clinical Oncology; May 31 - June 4, 2024. Abstract LBA1000.
  26. Trastuzumab deruxtecan (T-DXd) [prescribing information]. Basking Ridge, NJ: Daiichi Sankyo, Inc; 2025.
  27. Bardia A, Hu X, Dent R, et al. Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer. N Engl J Med. 2024;391:2110-2122.
  28. Bardia A, Hu X, Dent R, et al. Efficacy and safety of trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) by pace of disease progression on prior endocrine-based therapy: additional analysis from DESTINY-Breast06. Presented at: 2024 San Antonio Breast Cancer Symposium; December 10-13, 2024. Abstract LB1-04.
  29. Stagg J, Loi S, Divisekera U, et al. Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc Natl Acad Sci U S A. 2011;108:7142.
  30. Cortes J, Cescon DW, Rugo HS, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020;396:1817-1828.
  31. Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382:810-821.
  32. Loi S, Giobbie-Hurder A, Gombos A, et al. Pembrolizumab plus trastuzumab in trastuzumab resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial. Lancet Oncol. 2019;20:371-382.
  33. McArthur H, Chan I, Leal J, et al. A phase 2 study of neoadjuvant HER2-targeted therapy +/- immunotherapy with pembrolizumab (neoHIP). Presented at: 2024 San Antonio Breast Cancer Symposium; December 10-13, 2024. Abstract 2436.
  34. Metzger O, Mandrekar S, DeMichele A, et al. A randomized, open-label, phase III trial to evaluate the efficacy and safety of palbociclib + anti-HER2 therapy + endocrine therapy vs anti-HER2 therapy + endocrine therapy after induction treatment for hormone receptor positive (HR+)/HER2-positive metastatic breast cancer. Presented at: 2024 San Antonio Breast Cancer Symposium; December 10-13, 2024. Abstract GS2-12.
  35. Schmid P, Cortes J, Dent R, et al. Event-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med. 2022;386:556-567.
  36. Schmid P, Cortes, Dent R, et al. Overall survival with pembrolizumab in early-stage triple negative breast cancer. N Engl J Med. 2024;391:1981-1991.
  37. O’Shaughnessy J, Cortes J, Dent R, et al. Exploratory biomarker analysis of the phase 3 KEYNOTE-522 study of neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for early-stage TNBC. Presented at: 2024 San Antonio Breast Cancer Symposium; December 10-13, 2024. Abstract LB1-07.
  38. Dent R, Schmid P, Cortes J, et al. Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for high-risk, early-stage triple-negative breast cancer: overall survival and subgroup results from the phase 3 KEYNOTE-522 study. Presented at: 2024 San Antonio Breast Cancer Symposium; December 10-13, 2024. Abstract PS12-09.
  39. Geyer CE, Tang G, Nekljudova V, et al. NSABP B-59/GBG-96-GeparDouze: a randomised double-blind phase III clinical trial of neoadjuvant chemotherapy with atezolizumab or placebo followed by adjuvant atezolizumab or placebo in patients with stage II and III triple-negative breast cancer. Presented at: 2024 San Antonio Breast Cancer Symposium; December 10-13, 2024. Abstract GS3-05.
  40. Pembrolizumab [prescribing information]. Rahway, NJ: Merck & Co; 2024.